- Seegene's Italian subsidiary to supply some 7.15 million
COVID-19 tests to 17 regions there
- S. Korean biotechnology firm to expand its influence in
Italy's PCR diagnostic
industry
SEOUL, South Korea,
April 15, 2021 /PRNewswire/ --
Seegene Inc. (KQ 096530), a leading molecular diagnostics firm said
its Italian subsidiary, the Arrow Diagnostics Srl, has secured the
public procurement worth over EUR 89.3
million, the largest volume of tender in the history of its
Italian branch since 2014.
Under the tender agreement, the Arrow Diagnostics will supply
some 7.15 million COVID-19 diagnostic tests along with extraction
reagents to the Extraordinary Commissioner for COVID-19 Emergency,
or 'il commissario straordinario per l'emergenza COVID-19,' under
the Italian Ministry of Defense. The COVID-19 diagnostic tests will
be distributed to 17 regions including Lombardy, Tuscany, Veneto and Liguria.
Seegene's COVID-19 diagnostic test, the AllplexTM
SARS-CoV-2 Assay is a unique multiplex real-time PCR assay capable
of detecting a total of five target genes including four
coronavirus genes (E gene, RdRP gene, N gene and S gene) and an
exogenous control (entire whole process control) in a single
reaction, allowing highly accurate results and maximize throughput
for high volume testing. The diagnostic test has acquired CE-IVD
mark in June of 2020.
Seegene official added that with its technological advancement
of targeting multiple genes in a single reaction has an upper hand
in accurately and comprehensively detecting coronavirus even with
the recent uptick in its virus variants.
Also available with the COVID-19 diagnostic assay is
extraction-free application, which allows labs without extraction
equipment or reagent shortage to test samples for the coronavirus
in an even shorter turnaround time (TAT). The official added the
extraction-free application of the assay will help expedite the
control of pandemic.
The COVID-19 diagnostic tests as well as its extraction reagents
have already been supplied to Europe's third largest economy—and is in the
process of being allocated to regions nationwide since the start of
April.
An official from Seegene said that the company ultimately hopes
to put an end to the deadly pandemic by consistently supplying
COVID-19 diagnostic tests to countries around the world, and added
that it will continue to fulfill the duty as a leading global
diagnostics company by closely monitoring and studying the
development of the pandemic.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/seegenes-italy-subsidiary-secures-public-procurement-for-7-15-million-covid-19-diagnostic-tests-the-largest-tender-in-history-301269484.html
SOURCE Seegene Inc.